Left bundle branch area pacing for heart failure patients requiring cardiac resynchronization therapy: a meta-analysis

Chengyue Jin¹, Qiying Dai², Pengyang Li³, Patrick Lam¹, and Yong-Mei Cha²

¹Icahn School of Medicine at Mount Sinai Division of Cardiology ²Mayo Clinic Department of Cardiovascular Medicine ³Virginia Commonwealth University Division of Cardiology

March 1, 2023

Abstract

Background: Left bundle area branch pacing (LBBP) is a novel conduction system pacing method to achieve effective physiological pacing and an alternative to cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) for patients with heart failure and reduced ejection fraction (HFrEF). Objective: To review current data comparing BVP and LBBP in patients with HFrEF and indication CRT. Methods: We searched PubMed/Medline, Web of Science, and Cochrane Library from the inception of the database to November 2022. All studies that compared LBBP with BVP in patients with HFrEF and indications of CRT were included. Two reviewers performed the study selection, data abstraction, and risk of bias assessment. We calculated risk ratios with the Mantel-Haenszel method and mean difference with inverse variance using random effect models. We assessed heterogeneity using the I 2 index, with I $^2 > 50\%$ indicating significant heterogeneity. **Results:** Ten studies (9 observational studies and 1 randomized controlled trial; 616 patients; 15 centers) published between 2020 and 2022 were included. We observed a shorter fluoroscopy time [mean difference (MD) 9.68, 95% CI 4.49-14.87, I ²=95%, P<0.01, minutes] as well as a shorter procedure time (MD 33.68, 95% CI 17.80-49.55, I ²=73%, P<0.01, minutes) during implantation of LBBP CRT compared to conventional BVP CRT. LBBP was shown to have a greater reduction in QRSd (MD 25.13, 95%CI 20.06-30.20, I²= 51%, P<0.01, milliseconds) a greater left ventricular ejection fraction (LVEF) improvement (MD 5.80, 95% CI 4.81-6.78, I²=0%, P<0.01, percentage) and a greater ventricular end-diastolic diameter (LVEDD) reduction (MD 2.11, 95% CI 0.12-4.10, I²=18%, P=0.04, millimeter). There was a greater improvement in New York Heart Association function (NYHA) class with LBBP (MD 0.37, 95% CI 0.05-0.68, I²=61%, P=0.02).LBBP was also associated with a lower risk of a composite of heart failure hospitalizations and all-cause mortality [Risk ratio (RR) 0.48, 95% CI 0.25-0.90, I²=0%, p=0.02] driven by reduced heart failure hospitalizations (RR 0.39, 95% CI 0.19-0.82, I²=0%, p=0.01). However, all-cause mortality rates were low in both groups (1.52% vs. 1.13%) and similar (RR 0.98, 95% CI 0.21-4.68, I²=0%, p=0.87). Conclusion: Compared to BVP, LBBP is associated with, a greater improvement in LV systolic function, and a lower rate of heart failure-related hospitalization. Dedicated randomized controlled trials and larger patient populations are needed to further elucidate the long-term safety and efficacy of LBBP CRT.

Introduction

Heart failure is a global health problem, with over 64 million patients worldwide and over one million hospitalizations annually in the United States alone^{1, 2}. Heart failure with reduced ejection fraction (HFrEF) can be associated withleft and right ventricle desynchrony, which is hemodynamically disadvantageous and related to increased mortality³. Cardiac resynchronization therapy (CRT) is an established effective treatment for selected patients with HFrEF and , abnormal ventricular conduction resulting in wide QRS complex⁴⁻⁸. Conventionally, CRT is achieved by right ventricular and left ventricular pacing via coronary sinus (biventricular pacing, BVP). However, the success rate is highly related to coronary sinus anatomy (small caliber target vessels, tortuosity, and coronary sinus valves), and up to 30% of patients do not adequately respond to BVP CRT^{5, 9, 10}.

Conduction system pacing (CSP), including His bundle pacing (HBP) and left bundle branch area pacing (LBBP), was introduced in an attempt to mitigate these challenges by physiologically pacing the His-Purkinje system. His bundle pacing, however, requires a higher pacing threshold, and may not correct left bundle branch block (LBBB) below the level of His bundle¹¹⁻¹⁴. LBBP was first introduced in 2017 in humans and has emerged as a feasible and safe alternative to BVP to achieve cardiac resynchronization with accumulating supporting data¹⁵⁻¹⁸. Hence, the objective of this study was to conduct a systematic review and meta-analysis of current studies to compare the efficacy of LBBP and BVP CRT in HFrEF patients.

Method

Search strategy

This systemic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement¹⁹.

A literature search of PubMed/Medline, Web of Science, and Cochrane Library were performed from the inception of the database to November 30, 2022, was performed. We also searched ongoing trials at clinical-trials.gov and controlled-trials.com.

Study and Patient Selection

Institutional Review Board review is not required for meta-analyses because only de-identified, publicallyavailable data were used and no human subjects involvement²⁰. We included all studies that: (1) reported permanent LBBP, (2) were in English, (3) included patients [?]18 years old, (4) had a previous diagnosis of HFrEF, (5) with an indication for CRT, (6)compared with BVP. Case reports, abstracts, editorials/letters, reviews, and studies with fewer than 5 patients were excluded. The study contained the most data included if multiple publications were generated from the same patient cohort. Two authors (C Jin and Q Dai) independently extracted data from the selected studies. A third reviewer was consulted (P Li) was consulted in the instance of a disagreement.

Meta-analysis

Heterogeneity was assessed using the I^2 index, with $I^2 > 50\%$ indicating significant heterogeneity²¹. Continuous variables of interest were described with means, standard deviations, and sample size to estimate confidence intervals (CIs). Dichotomous variables were described using numerators and denominators to estimate proportions and CIs. The random effects model was used to estimate summary statistics for variables of interest, where individual studies were treated as a random variable. To estimate the difference in variables of interest over time, only publications that contained both baseline and follow-up means and standard deviations were used. We calculated risk ratios using the Mantel-Haenszel method and the mean difference with inverse variance. All statistical analyses were performed using Review Manager 5.3 software (Cochrane).

Result

Main findings

A total of 1,604 publications were identified, and 1,225 were screened after excluding duplicates. Twenty full-text articles were assessed for eligibility after 1,205 were excluded with abstract and title screening. After the assessment of full-text articles, 10 publications were excluded for: no LBBP group data separately reported from HBP/CSP group, no human study, published study protocol without data, and no control group with BVP. Ten studies (9 observational studies and 1 randomized controlled trial) were included (Figure 1).

The included studies comprised 616 patients across 15 centers, enrolled from December 2012 to June 2021, with the median being 2019 (Table 1). Patient baseline characteristics were reported in all studies (Table 2).

Left ventricular ejection fraction (LVEF) improvement was reported in all 10 studies. Compared to BVP, LBBP was associated with greater improvement (MD 5.80, 95% CI 4.81-6.78, $I^2=0\%$, P<0.01, percentage) at the end of follow-up period. Left ventricular end-diastolic diameter (LVEDD) reduction was also higher in the LBBP group (MD 2.11, 95% CI 0.12-4.10, $I^2=18\%$, P=0.04, millimeter). There was a greater improvement in New York Heart Association function (NYHA) class with LBBP (MD 0.37, 95% CI 0.05-0.68, $I^2=61\%$, P=0.02). Figure 2.

A composite outcome of heart failure-related hospitalization (HFH) and all-cause mortality was also lower with LBBP compared to BVP CRT [Risk ratio (RR) 0.48, 95% CI 0.25-0.90, $I^2=0\%$, p=0.02] driven mainly by heart failure hospitlizations (HFH) reduction (RR 0.39, 95% CI 0.19-0.82, $I^2=0\%$, p=0.01). However, allcause mortality rates were low in both groups (1.52% vs. 1.13%) and similar (RR 0.98, 95%CI 0.21-4.68, $I^2=0\%$, p=0.87). Figure 3.

Pacing outcomes

LBBP was associated with a lower chronic pacing threshold (MD 0.56, 95% CI 0.47-0.64, $I^2=39\%$, P<0.01, volts) and a lower impedance (MD 81.02, 95% CI 24.65-137.40, $I^2=69\%$, P<0.01, ohm) on follow up.

All publications reported reduction of QRS duration (QRSd) with LBBP; however, 1 study did not report the data for BVP. LBBP was shown to have a greater reduction in QRSd (MD 25.13, 95%CI 20.06-30.20, $I^2 = 51\%$, P<0.01, milliseconds). Figure 4.

Procedure duration and fluororoscopy time

We observed a shorter fluoroscopy time [mean difference (MD) 9.68, 95% CI 4.49-14.87, $I^2=95\%$, P<0.01, minutes] as well as a shorter procedure time (MD 33.68, 95% CI 17.80-49.55, $I^2=73\%$, P<0.01, minutes) during implantation of LBBP CRT compared to BVP CRT. Figure 5.

Procedure success rate and complications

All studies exclusively used a fixed curve sheath (C315 HIS, Medtronic Inc., Minneapolis, MN, USA) and the Select Secure pacing lead (model 3830, Medtronic Inc., Minneapolis, MN, USA) except for Wu *et al.*,in whose study also used a deflectable delivery system (C304, Medtronic Inc., Minneapolis, MN, USA)²². The overall implant success rate was 88.3%, ranging from 77.5% to 98%. The most common reason for implant failure was difficulty/inability to penetrate the septum, representing 41.67% of all failures.

Eight studies reported procedure-related complications (Table 3). There were 15 complications observed in 245 patients. The most commonly reported complication was transient right bundle branch injury (14 total complications). The only other complication reported was one case of lead dislodgement.

Discussion

We systematically reviewed 10 original studies comparing LBBP and BVP CRT, which were comprised of patients from 15 centers around the world. This is the largest, most up-to-date systemic review and metaanalysis to demonstrate the effectiveness and safety of LBBP CRT to our knowledge. We found 1) performing LBBP compared to BVP is associated with shorter procedure and fluoroscopy time. 2) LBBP is associated with a greater reduction in QRSd and greater LVEF improvement. 3) A composite of HFH hospitalization and all-cause mortality had a greater reduction with LBBP as well as a greater improvement in overall function. However, the reported mortality was low and there was no difference in all-cause mortality alone. The overall implant success rate was approaching 90% and complication rates were low. Comparison of implant success rate of LBBP and BVP was not performed because most included studies only included historical cohor for BVP which only consist of successfully implanted cases.

Since the introduction of LBBP, multiple studies have explored the feasibility, safety, and clinical comparison of other existing pacing methods in various indications including heart failure requiring CRT²³⁻³⁰. A previous study had shown LBBP, if optimized AV delay, can achieve better interventricular synchrony compared to BVP in ex-vivo heart models¹⁸. A retrospective cohort of 34 patients who underwent LBBP CRT with a

follow-up period of 12 months observed a significant decrease in QRSd, and improvement in LVEF, LVEDD, NYHA classification, brain natriuretic peptide (BNP) level, and 6-minute walk test (6MWT). The success rate of LBBP in the cohort was 100% with stable pacing capture threshold and R-wave amplitude at the end of 12 months follow-up²³. Another study that compared CSP (87 HBP and 171 LBBP) and BVP also noted a significantly narrower QRSd, greater LVEF improvement, and lower composite of HFH and mortality³¹.

Our findings were also consistent with recently published Left bundle branch area pacing outcomes: the multicenter European (MELOS) study and the Left Ventricular Activation Time Shortening With Conduction System Pacing vs Biventricular Resynchronization Therapy (LEVEL-AT) trial^{32, 33}. The MELOS study was a registry-based observational study comprised of 2,533 patients attempted LBBP with 27.5% of whom had an indication from heart failure. The reported implant success rate in heart failure indication was 82.2%, which was similar to our finding. The overall complication rate of LBBP in the MELOS study was 11.68% mainly driven by lead complications including left ventricle perforation and dislodgement, which was much higher than our finding. The LEVEL-AT trial was a randomized controlled noninferiority trial that compared ventricular synchrony in CSP including HBP and LBBP with BVP in HFrEF patients with indications for CRT. Of the 35 CSP patients included, the majority of them were allocated to LBBP (80%). It showed ventricular synchronization achieved by CSP was non-inferior to BVP. There was a trend towards a greater QRSd reduction and a lower composite of HFH or mortality after a 6-month follow-up period but no difference in LVEF improvement. The implant success rate of LBBP was 82% which was similar to our finding. The high crossover rate (8/35 crossed over from CSP to BVP and 2/35 corssed over from CVP to CSP) and small sample size of the trial might limit further interpretation of results.

The improvement in interventricular synchrony by EKG findings (QRSd) and clinical outcomes we had observed may not be limited to HFrEF patients but to patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with midrange ejection fraction (HFmrEF), as one recent study suggests²⁷. Echocardiographic parameters of interventricular synchrony assessment including interventricular mechanical delay (defined as difference between the pre-ejection intervals from QRS onset to the beginning of ventricular ejection at pulmonary and aortic valve level), the regional time intervals of left ventricular 12 segments between the onset of the QRS complex and the peak of systolic myocardial velocity during the ejection phase (Ts), standard deviation of Ts (Ts-SD) and peak strain dispersion had greater improvement with LBBP compared to BVP but they were only studied in two of included studies^{34, 35}.

Despite LBBP having greater hemodynamic improvement as well as lower HFH in our analysis, we did not observe a clear benefit in all-cause mortality compared to BVP CRT, which can be attributed to the short follow-up period by most studies included. This was evidenced by the lower-than-expected mortality rate. The short follow-up can also potentially preclude the delayed effect in mortality benefit by improved interventricular synchrony and hemodynamics.

In patients with failed BVP due to CS lead failure or nonresponsive to BVP, it has been demonstrated that LBBP can be a safe and viable alternative ³⁶. In the 2021 ESC Guidelines on Cardiac Pacing and CRT, there was no official recommendation for LBBP pending more evidence for long-term safety and efficacy from randomized trials³⁷.

With shorter procedural and fluoroscopy time and possible improved clinical outcomes, LBBP is a promising and emerging alternative to BVP. Further studies, especially randomized controlled trials are required to demonstrate the long-term safety and efficacy of LBBP, and further, elucidate the clinical benefit of LBBP CRT. ChiCTR200028726 is an ongoing single-center randomized controlled noninferiority trial aiming to recruit 180 patients with HFrEF and indication of CRT³⁸. Patients will be randomized at a 1:1 ratio to LBBP or BVP CRT. The recruitment period concluded in December 2022. The completion of this trial and other ongoing trials can potentially better demonstrate the role of LBBP CRT.

Limitations

Our meta-analysis had several limitations: First, only one study included in our analysis was a randomized control trial and the other 9 were observational studies, which can potentially introduce confounding factors

and compromise the interpretation of results. Second, all 10 studies had a relatively small sample size and short follow-up period, limiting the power to assess the long-term outcome and safety of LBBP. Third, the definition and classification of data reporting in different studies varies (e.g. definition of implant success, use of BNP versus N-terminal-pro BNP, etc.) thereby limiting further data extraction and analysis.

Conclusion

Compared to BVP, LBBP is associated with, a greater improvement in LV systolic function, and a lower rate of heart failure-related hospitalization from this meta-analysis. Dedicated large randomized controlled trials are needed to further elucidate the comparative long-term efficacy and safety of LBBP CRT vs. BIV CRT.

References:

1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Nov 10 2018;392:1789-1858.

2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation Feb 23 2010;121:e46-e215.

3. Baldasseroni S, Gentile A, Gorini M, Marchionni N, Marini M, Masotti G, Porcu M, Maggioni AP. Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). Ital Heart J Sep 2003;4:607-613.

4. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145.

5. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, Page RL, Hlatky MA, Rowe BH. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. Jama Jun 13 2007;297:2502-2514.

6. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation Mar 15 2011;123:1061-1072.

7. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England journal of medicine Apr 14 2005;352:1539-1549.

8. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. New England Journal of Medicine 2004/05/20 2004;350:2140-2150.

9. Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. European heart journal May 14 2017;38:1463-1472.

10. Hummel JD, Coppess MA, Osborn JS, Yee R, Fung JW, Augostini R, Li S, Hine D, Singh JP. Real-World Assessment of Acute Left Ventricular Lead Implant Success and Complication Rates: Results from the Attain Success Clinical Trial. Pacing Clin Electrophysiol Nov 2016;39:1246-1253.

11. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Mao G, Vijayaraman P, Ellenbogen KA. Long-term outcomes of His bundle pacing in patients with heart failure with left bundle branch block. Heart Jan 2019;105:137-143.

12. Lewis AJM, Foley P, Whinnett Z, Keene D, Chandrasekaran B. His Bundle Pacing: A New Strategy for Physiological Ventricular Activation. Journal of the American Heart Association 2019;8:e010972.

13. Vinther M, Risum N, Svendsen JH, Møgelvang R, Philbert BT. A Randomized Trial of His Pacing Versus Biventricular Pacing in Symptomatic HF Patients With Left Bundle Branch Block (His-Alternative). 2021;7:1422-1432.

14. Sharma PS, Dandamudi G, Herweg B, Wilson D, Singh R, Naperkowski A, Koneru JN, Ellenbogen KA, Vijayaraman P. Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: A multicenter experience. Heart rhythm 2018;15:413-420.

15. Huang W, Su L, Wu S, Xu L, Xiao F, Zhou X, Ellenbogen KA. A Novel Pacing Strategy With Low and Stable Output: Pacing the Left Bundle Branch Immediately Beyond the Conduction Block. Can J Cardiol Dec 2017;33:1736 e1731-1736 e1733.

16. Vijayaraman P, Ponnusamy S, Cano O, et al. Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: Results From the International LBBAP Collaborative Study Group. JACC Clinical electrophysiology 2021;7:135-147.

17. Wang Y, Zhu H, Hou X, et al. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. Journal of the American College of Cardiology 2022/09/27/ 2022;80:1205-1216.

18. Strocchi M, Lee AWC, Neic A, et al. His-bundle and left bundle pacing with optimized atrioventricular delay achieve superior electrical synchrony over endocardial and epicardial pacing in left bundle branch block patients. Heart rhythm 2020;17:1922-1929.

19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj Jul 21 2009;339:b2535.

20. Medicine ISo. Program for the Protection of Human Subjects / Institutional Review Board. 2023; https://icahn.mssm.edu/about/faculty-resources/handbook/research/irb, 2023.

21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj Sep 6 2003;327:557-560.

22. Wu S, Su L, Vijayaraman P, Zheng R, Cai M, Xu L, Shi R, Huang Z, Whinnett ZI, Huang W. Left bundle branch pacing for Cardiac Resynchronization Therapy: non-randomized on treatment comparison with His Bundle Pacing and Biventricular Pacing. 2020.

23. Gu Y, Li Y, Zhu Y, Lin X, Tian T, Zhang Q, Gong J, Wang L, Li J. Cardiac resynchronization therapy in heart failure patients by using left bundle branch pacing. Frontiers in cardiovascular medicine 2022;9:990016.

24. Feng XF, Yang LC, Zhao Y, Yu YC, Liu B, Li YG. Effects of adaptive left bundle branch-optimized cardiac resynchronization therapy: a single centre experience. BMC Cardiovasc Disord Aug 6 2022;22:360.

25. Vijayaraman P, Cano O, Ponnusamy SS, et al. Left bundle branch area pacing in patients with heart failure and right bundle branch block: Results from International LBBAP Collaborative-Study Group. Heart Rhythm O2 2022;3:358-367.

26. Sharma PS, Patel NR, Ravi V, et al. Clinical outcomes of left bundle branch area pacing compared to right ventricular pacing: Results from the Geisinger-Rush Conduction System Pacing Registry. Heart Rhythm Jan 2022;19:3-11.

27. Okubo Y, Miyamoto S, Uotani Y, Ikeuchi Y, Miyauchi S, Okamura S, Tokuyama T, Nakano Y. Clinical impact of left bundle branch area pacing in heart failure with preserved ejection fraction and mid-range ejection fraction. Pacing Clin Electrophysiol Apr 2022;45:499-508.

28. Padala SK, Master VM, Terricabras M, Chiocchini A, Garg A, Kron J, Shepard R, Kalahasty G, Azizi Z, Tsang B, et al. Initial Experience, Safety, and Feasibility of Left Bundle Branch Area Pacing: a Multicenter Prospective Study. 2020.

29. Ravi V, Hanifin JL, Larsen T, Huang HD, Trohman RG, Sharma PS. Pros and Cons of Left Bundle Branch Pacing: A Single-Center Experience. Circulation Arrhythmia and electrophysiology 2020;13:e008874.

30. Su L, Wang S, Wu S, Xu L, Huang Z, Chen X, Zheng R, Jiang L, Ellenbogen KA, Whinnett ZI, Huang W. Long-Term Safety and Feasibility of Left Bundle Branch Pacing in a Large Single-Center Study. Circulation Arrhythmia and electrophysiology 2021;14:e009261.

31. Vijayaraman P, Zalavadia D, Haseeb A, et al. Clinical outcomes of conduction system pacing compared to biventricular pacing in patients requiring cardiac resynchronization therapy. Heart rhythm 2022;19:1263-1271.

32. Jastrzębski M, Kiełbasa G, Cano O, et al. Left bundle branch area pacing outcomes: the multicentre European MELOS study European heart journal 2022;43:4161-4173.

33. Pujol-Lopez M, Jiménez-Arjona R, Garre P, et al. Conduction System Pacing vs Biventricular Pacing in Heart Failure and Wide QRS Patients. JACC: Clinical Electrophysiology 2022/11/01 2022;8:1431-1445.

34. Liang Y, Wang J, Gong X, et al. Left Bundle Branch Pacing Versus Biventricular Pacing for Acute Cardiac Resynchronization in Patients With Heart Failure. Circulation Arrhythmia and electrophysiology Oct 28 2022e011181.

35. Liu W, Hu C, Wang Y, Cheng Y, Zhao Y, Liu Y, Zheng S, Chen H, Shu X. Mechanical Synchrony and Myocardial Work in Heart Failure Patients With Left Bundle Branch Area Pacing and Comparison With Biventricular Pacing. Frontiers in cardiovascular medicine 2021;8:727611.

36. Vijayaraman P, Herweg B, Verma A, et al. Rescue left bundle branch area pacing in coronary venous lead failure or nonresponse to biventricular pacing: Results from International LBBAP Collaborative Study Group. Heart rhythm 2022;19:1272-1280.

37. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). European heart journal 2021;42:3427-3520.

38. Cheng L, Zhang J, Wang Z, Zhou M, Liang Z, Zhao L, Chen J, Wu Y. Efficacy and safety of left bundle branch area pacing versus biventricular pacing in heart failure patients with left bundle branch block: study protocol for a randomised controlled trial. 2020;10.

Table 1. Included studies in the meta-analysis

Publication	Year	Study	Center	Patient	Patient	Patient	Patient	Follow-up	Re
		type		Number	Number	Number	Number	(months)	
				(enrollment)	(enrollment)	(as	(as		
						treated)	treated)		
				BVP	LBBP	BVP	LBBP		
Guo et	2020	Observation	naSingle	21	24	21	21	6	As
al.									
Li et	2020	Observation	haMultiple	54	37	54	27	6	As
al.									
Wang	2020	Observation	naSingle	30	10	30	10	6	As
et al.									
Wu et	2020	Observation	naSingle	49	30	54	32	12	As
al.									

2021	$Observationa {\rm Multiple}$	28	34	35	27	6	As
2021	ObservationalSingle	22	10	19	13	12	As
2022	Observationa Multiple	56	50	51	49	12	As
2022	ObservationalSingle	20	21	20	21	24	As
2022	ObservationalSingle	40	40	38	31	6	Eu
2022	Randomized Multiple con- trolled trial	20	20	18	16	6	As
	2021 2022 2022 2022	2021ObservationalSingle2022ObservationalMultiple2022ObservationalSingle2022ObservationalSingle2022Randomized Multiple con- trolled	2021ObservationalSingle222022ObservationalMultiple562022ObservationalSingle202022ObservationalSingle402022Randomized Multiple con- trolled20	2021ObservationaSingle22102022ObservationaMultiple56502022ObservationaSingle20212022ObservationaSingle40402022Randomized Multiple con- trolled2020	2021Observationa Single2210192022Observationa Multiple5650512022Observationa Single2021202022Observationa Single4040382022Randomized Multiple202018	2021ObservationalSingle221019132022ObservationalMultiple565051492022ObservationalSingle202120212022ObservationalSingle404038312022Randomized Multiple20201816	2021ObservationalSingle22101913122022ObservationalMultiple56505149122022ObservationalSingle20212021242022ObservationalSingle4040383162022Randomized Multiple202018166

BVP, biventricular pacing with coronary sinus lead; LBBP, left bundle branch pacing.

Table2. Baseline Characteristics of LBBP Patients in Included Studies

Study	Inclusion criteria	Age (Years)	Gender (1
Guo et al.2020	LBBB, LVEF[?]35%, NYHA functional class II to IV	66.1 ± 9.7	42.9
Li et al. 2020	LBBB, LVEF [?] 35%, NYHA functional class II to IV	56.8 ± 10.1	59.5
Wang et al. 2020	Sinus rhythm, LBBB, LVEF[?]35%, NYHA functional class II to IV	64.80 ± 7.25	90
Wu et al. 2020	LBBB, LVEF[?]40%, NYHA functional class II to IV, failed HBP	67.2 ± 13	43.8
Liu et al. 2021	LBBB, LVEF [?]35%, NYHA functional class II to IV	65.5 ± 8.8	51.9
Zu et al. 2021	QRSd>150 ms, LBBB, LVEF<35%, NYHA functional class II to IV	61.77 ± 12.37	61.5
Chen <i>et al.</i> 2022	QRSd>150 ms, LBBB, LVEF $<35\%$, NYHA functional class II to IV	$67.14 \pm \ 8.88$	49.98
Hua <i>et al.</i> 2022	QRSd>150 ms, LBBB, LVEF<35%, NYHA functional class II to IV	65.50 ± 6.91	71.43
Rademakers et al. 2022	LBBB, LVEF[?]35%, NYHA functional class II to IV	68 ± 13	48
Wang et al. 2022	LBBB, LVEF[?]40%, NYHA functional class II to IV, NICM	62.3 ± 11.2	35

LBBP, left bundle branch area pacing; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; ICM, ischemic cardiomyopathy; NICM, non- ischemic cardiomyopathy; HBP, His bundle pacing; N/A, not available.

Table 3.	Complications	related to	LBBP	procedure

Study	Right bundle	Lead/ device	Coronary artery	Phrenic nerve	Chronic capture	Lead dislodgeme	Perforation nt	Embolism	Pn
	branch injury	infection	injury	stimulation	thresh- old elevation	distoldgomo.			
Guo et al.2020	4 (All self- resolved within 24 hours)	0	0	0	0	0	0	0	0
Li <i>et</i> <i>al.</i> 2020	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/

Wang et al.	0	0	0	0	0	0	0	0	0
2020 Wu <i>et</i> <i>al.</i>	0	0	0	0	0	0	0	0	0
2020 Liu <i>et</i> <i>al.</i> 2021	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/
Zu <i>et</i> <i>al.</i> 2021	0	0	0	0	0	0	0	0	0
Chen <i>et</i> <i>al.</i> 2022	10 (9 cases recovered prior to discharge)	0	0	0	0	0	0	0	0
Hua <i>et</i> <i>al.</i> 2022	0	0	0	0	0	0	0	0	0
Rademakers et al. 2022	0	0	0	0	0	0	0	0	0
Wang et al. 2022	0	0	0	0	0	1	0	0	0

LBBP, left bundle branch area pacing.




Figure 1: Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.

Depiction of selection of studies.

	nt I	LBBP			BVP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Chen2021	18.52	13.19	49	12.89	9.73	51	4.7%	5.63 [1.07, 10.19]	
Guo2020	20.5	9.6	21	15.4	11.2	21	2.5%	5.10 [-1.21, 11.41]	+
Hua2022	15.66	14.59	21	12.77	11.13	20	1.6%	2.89 [-5.03, 10.81]	
Li2020	17.1	7.2	27	7	7.5	54	8.6%	10.10 [6.73, 13.47]	
Liu2021	17.2	9.3	27	13.7	11.5	35	3.7%	3.50 [-1.68, 8.68]	
Rademakers2022	15.1	11.7	29	9.3	12.3	36	2.9%	5.80 [-0.05, 11.65]	
Wang2020	18.06	9.99	10	12.97	13.37	30	1.6%	5.09 [-2.73, 12.91]	
Wang2022	21.08	1.91	20	15.62	1.94	20	69.1%	5.46 [4.27, 6.65]	
Wu 2020	24	10.9	30	16.7	14.6	49	3.1%	7.30 [1.65, 12.95]	
Zu2021	18.3	10.66	13	13.42	6.87	19	2.3%	4.88 [-1.69, 11.45]	
Total (95% CI)			247			335	100.0%	5.80 [4.80, 6.79]	•
Heterogeneity: Tau² =					.51); I² =	= 0%			-10 -5 0 5 10
Test for overall effect:	Z=11.4	5 (P < 0	0.00001)					Favors BVP Favors LBBP
B. LVEDD Reduction		LBBP			BVP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% CI
Chen2021	12.57	12.8	49	7.39	18.49	51	9.0%	5.18 [-1.03, 11.39]	
Guo2020	11	16.4	21	9.4	14.4	21	4.3%	1.60 [-7.73 10.93]	
Hua2022	10.61	11.97	21	5.28	10.81	20	7.3%	5.33 [-1.65, 12.31]	
Rademakers2022	6.9	10.3	29	1.6	11.8	36	11.5%	5.30 [-0.08, 10.68]	
Wang2020	11.1	14.83	10	8.74	17.47	30	3.1%	2.36 [-8.76, 13.48]	
Wang2022	11.42	1.22	20	10.64	1.24	20	64.9%	0.78 [0.02, 1.54]	-
Total (95% CI)			150			178	100.0%	2.11 [0.12, 4.10]	◆
Heterogeneity: Tau ² =	= 1.43; C	hi² = 6.0)7,df=	5 (P = 0).30); l²:	= 18%			-10 -5 0 5 10
Test for overall effect	: Z = 2.08	8 (P = 0.	04)						Favours BVP Favours LBBP
. NYHA Class Improv	ement ,	RRD		r	R\/D			Mean Difference	
-	^{vernent} L Mean	LBBP SD	Total	-	SVP SD	Total		Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
. NYHA Class Improv Study or Subgroup Guo2020			Total 21	-		Total 21		IV, Random, 95% Cl	Mean Difference
Study or Subgroup	Mean 1.7	SD		Mean	SD 1.4		Weight		Mean Difference
Study or Subgroup Guo2020 Hua2022	Mean 1.7	SD 1.6	21	Mean 1.5	SD 1.4	21	Weight 8.8%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16]	Mean Difference
Study or Subgroup Guo2020 Hua2022 Liu2021	Mean 1.7 1.28 1.6	SD 1.6 1.46 0.6	21 21 27	Mean 1.5 1.11 0.9	SD 1.4 1.76 0.8	21 20 35	Weight 1 8.8% 7.7% 24.2%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16] 0.70 [0.35, 1.05]	Mean Difference
Study or Subgroup Guo2020 Hua2022 Liu2021 Wang2020	Mean 1.7 1.28 1.6 1.4	SD 1.6 1.46 0.6 1.29	21 21 27 10	Mean 1.5 1.11 0.9 1.1	SD 1.4 1.76 0.8 1.35	21 20 35 30	Weight 8.8% 7.7% 24.2% 8.4%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16] 0.70 [0.35, 1.05] 0.30 [-0.63, 1.23]	Mean Difference
Study or Subgroup Guo2020 Hua2022 Liu2021 Wang2020 Wang2022	Mean 1.7 1.28 1.6 1.4 1.22	SD 1.6 1.46 0.6 1.29 0.11	21 21 27 10 20	Mean 1.5 1.11 0.9 1.1 1.1	SD 1.4 1.76 0.8 1.35 0.11	21 20 35 30 20	Weight 1 8.8% 7.7% 24.2% 8.4% 34.2%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16] 0.70 [0.35, 1.05] 0.30 [-0.63, 1.23] 0.12 [0.05, 0.19]	Mean Difference IV, Random, 95% Cl
Study or Subgroup Guo2020 Hua2022 Liu2021 Wang2020	Mean 1.7 1.28 1.6 1.4	SD 1.6 1.46 0.6 1.29	21 21 27 10	Mean 1.5 1.11 0.9 1.1	SD 1.4 1.76 0.8 1.35	21 20 35 30	Weight 8.8% 7.7% 24.2% 8.4%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16] 0.70 [0.35, 1.05] 0.30 [-0.63, 1.23]	Mean Difference IV, Random, 95% Cl
Study or Subgroup Guo2020 Hua2022 Liu2021 Wang2020 Wang2022 Wu 2020 Total (95% CI)	Mean 1.7 1.28 1.6 1.4 1.22 1.5	SD 1.6 1.46 0.6 1.29 0.11 1	21 27 10 20 30 129	Mean 1.5 1.11 0.9 1.1 1.1 0.9 0.9	SD 1 1.4 1.76 0.8 1.35 0.11 1.5	21 20 35 30 20 49 175	Weight 8.8% 7.7% 24.2% 8.4% 34.2% 16.7% 100.0%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16] 0.70 [0.35, 1.05] 0.30 [-0.63, 1.23] 0.12 [0.05, 0.19]	Mean Difference IV, Random, 95% Cl
Study or Subgroup Guo2020 Hua2022 Liu2021 Wang2020 Wang2022 Wu 2020	Mean 1.7 1.28 1.6 1.4 1.22 1.5	SD 1.6 1.46 0.6 1.29 0.11 1	21 27 10 20 30 129	Mean 1.5 1.11 0.9 1.1 1.1 0.9 0.9	SD 1 1.4 1.76 0.8 1.35 0.11 1.5	21 20 35 30 20 49 175	Weight 8.8% 7.7% 24.2% 8.4% 34.2% 16.7% 100.0%	V, Random, 95% Cl 0.20 [-0.71, 1.11] 0.17 [-0.82, 1.16] 0.70 [0.35, 1.05] 0.30 [-0.63, 1.23] 0.12 [0.05, 0.19] 0.60 [0.05, 1.15]	Mean Difference IV, Random, 95% Cl

Figure 2: (A) Left ventricular ejection fraction improvement from baseline to longest follow-up, percent. (B) Left ventricular end-diastolic diameter reduction from baseline to longest follow-up, millimeter. (C) Improvement of NYHA function class. LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; NYHA, New York Heart Association; SD, standard deviation; CI, confidence interval; LBBP, left bundle branch area pacing; BVP, biventricular pacing.

	and Mortal LBBF		BVP			Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Chen2021	2	49	5	51	15.7%	0.42 [0.08, 2.05]			
Guo2020	0	21	0	21		Not estimable			
Hua2022	5	21	12	20	55.7%	0.40 [0.17, 0.92]			
Li2020	0	27	0	54		Not estimable			
Rademakers2022	3	29	4	36	19.9%	0.93 [0.23, 3.83]			
Wang2020	0	10	1	30	4.1%	0.94 [0.04, 21.40]			
Wu 2020	0	30	3	49	4.6%	0.23 [0.01, 4.31]			
Total (95% CI)		187		261	100.0%	0.48 [0.25, 0.90]		•	
Total events	10		25						
Heterogeneity: Tau ² =	0.00; Chi	² = 1.49	9, df = 4 (P = 0.8	3); I ² = 09	6	0.01	0.1 1 10	1
Test for overall effect:	Z=2.29 (P = 0.0	2)				0.01	Favors LBBP Favors BVP	11
B. HFH	LBBF	р	BVP			Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Chen2021	2	49	5	51	21.2%	0.42 [0.08, 2.05]			
Guo2020	0	21	0	21		Not estimable			
Hua2022	4	21	11	20	57.4%	0.35 [0.13, 0.91]			
Li2020	0	27	0	54		Not estimable			
Rademakers2022	1	29	2	36	9.7%	0.62 [0.06, 6.51]			
Wang2020	Ó	10	1	30	5.5%	0.94 [0.04, 21.40]			
Wu 2020	Ō	30	3	49	6.3%	0.23 [0.01, 4.31]			
Total (95% CI)		187		261	100.0%	0.39 [0.19, 0.82]		•	
Total events	7		22						
Heterogeneity: Tau ² =	0.00; Chi	² = 0.64	4. df = 4 (P = 0.9	6); I ² = 09	6	L		
Test for overall effect:							0.01	0.1 1 10 Favors LBBP Favors BVP	1
C. All-cause Mortality	LBBF		BVP			Risk Ratio		Risk Ratio	
2		p			Weight	Risk Ratio M-H, Random, 95% Cl		Risk Ratio M-H, Random, 95% Cl	
Study or Subgroup	Events	p Total	Events	Total	Weight	M-H, Random, 95% Cl			
Study or Subgroup Chen2021	Events 0	p Total 49	Events 0	Total 51	Weight	M-H, Random, 95% Cl Not estimable			
Study or Subgroup Chen2021 Guo2020	Events 0 0	p Total 49 21	Events 0 0	Total 51 21		M-H, Random, 95% CI Not estimable Not estimable			
Study or Subgroup Chen2021 Guo2020 Hua2022	Events 0 0 1	p Total 49 21 21	Events 0 0 1	Total 51 21 20	Weight 33.0%	M-H, Random, 95% CI Not estimable Not estimable 0.95 [0.06, 14.22]			
Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020	Events 0 0 1 0	70tal 49 21 21 27	Events 0 1 0	Total 51 21 20 54	33.0%	M-H, Random, 95% CI Not estimable Not estimable 0.95 [0.06, 14.22] Not estimable			
Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022	Events 0 1 0 2	P Total 49 21 21 27 29	Events 0 1 0 2	Total 51 21 20 54 36		M-H, Random, 95% CI Not estimable Not estimable 0.95 [0.06, 14.22] Not estimable 1.24 [0.19, 8.28]			
Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022 Wang2020	Events 0 1 0 2 0	7 70tal 49 21 21 21 27 29 10	Events 0 0 1 0 2 0	Total 51 20 54 36 30	33.0%	M-H, Random, 95% CI Not estimable Not estimable 0.95 [0.06, 14.22] Not estimable 1.24 [0.19, 8.28] Not estimable			
Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022 Wang2020	Events 0 1 0 2	P Total 49 21 21 27 29	Events 0 1 0 2	Total 51 21 20 54 36	33.0%	M-H, Random, 95% CI Not estimable Not estimable 0.95 [0.06, 14.22] Not estimable 1.24 [0.19, 8.28]			
Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022 Wang2020 Wu 2020	Events 0 1 0 2 0	7 70tal 49 21 21 21 27 29 10	Events 0 0 1 0 2 0	Total 51 20 54 36 30 49	33.0%	M-H, Random, 95% CI Not estimable Not estimable 0.95 [0.06, 14.22] Not estimable 1.24 [0.19, 8.28] Not estimable			
C. All-cause Mortality <u>Study or Subgroup</u> Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022 Wang2020 Wu 2020 Total (95% CI) Total events	Events 0 1 0 2 0	70tal 49 21 21 27 29 10 30	Events 0 0 1 0 2 0	Total 51 20 54 36 30 49	33.0% 67.0%	M-H, Random, 95% Cl Not estimable Not estimable 0.95 [0.06, 14.22] Not estimable 1.24 [0.19, 8.28] Not estimable Not estimable			

Figure 3: (A) Composite outcome of heart failure-related hospitalizations and all-cause mortality, number of event. (B) Heart failure-related hospitalizations, number of event. (C) All-cause mortality, number of event. HFH, heart failure-related hospitalizations; CI, confidence interval; LBBP, left bundle branch area pacing; BVP, biventricular pacing; M-H, Mantel-Haenszel method.





Figure 4: (A) Pacing impedance at longest follow-up, ohm. (B) Pacing threshold at longest follow-up, volts. (C) QRS duration reduction, millisecond. QRSd, QRS duration; CI, confidence interval; LBBP, left bundle branch area pacing; BVP, biventricular pacing; SD, standard deviation.

	L	BBP			BVP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chen2021	9.5	1.99	49	13.84	5.47	51	15.3%	-4.34 [-5.94, -2.74]	+
Hua2022	20.14	6.05	21	26.5	4.07	20	14.7%	-6.36 [-9.50, -3.22]	
Li2020	16.9	6.4	27	39.6	9.2	54	14.6%	-22.70 [-26.14, -19.26]	
Rademakers2022	14	10	31	15	10	38	13.8%	-1.00 [-5.74, 3.74]	
Wang2022	11.95	5.77	20	18.66	10.12	20	13.5%	-6.71 [-11.82, -1.60]	
Wu 2020	5.2	4.1	30	10.3	4.4	49	15.2%	-5.10 [-7.02, -3.18]	-
Zu2021	20.46	7.36	13	43.53	10.36	19	12.8%	-23.07 [-29.21, -16.93]	— —
Total (95% CI)			191			251	100.0%	-9.68 [-14.87, -4.49]	•
Heterogeneity: Tau² Test for overall effect		(P = 0	.0003)						-20 -10 0 10 20 Favors LBBP Favors BVP
	: Z = 3.66		.0003)		BVP			Mean Difference	Favors LBBP Favors BVP
Test for overall effect B. Procedure Time	: Z = 3.66	.BBP	,	Mea	BVP) Tota	al Weight	Mean Difference IV. Random, 95% Cl	Favors LBBP Favors BVP
Test for overall effect B. Procedure Time Study or Subgroup	: Z = 3.66 I Mean	.BBP SD	Total		i SI		nl Weight	IV, Random, 95% Cl	Favors LBBP Favors BVP
Test for overall effect B. Procedure Time Study or Subgroup Hua2022	: Z = 3.66	.BBP SD	Total 21	127.	1 SI 3 24.7	1 2	0 23.3%	IV, Random, 95% Cl -23.56 [-36.69, -10.43]	Favors LBBP Favors BVP
Test for overall effect B. Procedure Time Study or Subgroup Hua2022 Rademakers2022	: Z = 3.66	.BBP SD 17.36	Total 21 31	127.) 13	1 SI 3 24.7 7 4	1 2 8 3	0 23.3% 8 19.9%	IV, Random, 95% Cl -23.56 [-36.69, -10.43] -28.00 [-46.97, -9.03]	Favors LBBP Favors BVP
Test for overall effect	EZ = 3.66	.BBP SD 17.36 32	Total 21 31 20	127. 13 155.9	1 SI 3 24.7 7 4 2 40.	1 2 8 3 7 2	0 23.3% 8 19.9% 0 17.8%	V, Random, 95% Cl -23.56 [-36.69, -10.43] -28.00 [-46.97, -9.03] -26.67 [-49.28, -4.06]	Favors LBBP Favors BVP
Test for overall effect B. Procedure Time Study or Subgroup Hua2022 Rademakers2022 Wang2022	Z = 3.66 Mean 104.24 109 129.25	.BBP SD 17.36 32 31.69	Total 21 31 20 32	127. 13 155.9 122.	1 SI 3 24.7 7 4 2 40.	1 2 8 3 7 2 5 5	0 23.3% 8 19.9% 0 17.8% 4 19.8%	V, Random, 95% Cl -23.56 [-36.69, -10.43] -28.00 [-46.97, -9.03] -26.67 [-49.28, -4.06] -24.30 [-43.37, -5.23]	Favors LBBP Favors BVP
B. Procedure Time Study or Subgroup Hua2022 Rademakers2022 Wuang2022 Wu 2020	E Z = 3.66 Mean 104.24 109 129.25 98.4	BBP 5D 17.36 32 31.69 36.5	Total 21 31 20 32	127.3 13 155.9 122.3 158.0	1 SI 3 24.7 7 4 2 40. 7 53.	1 2 8 3 7 2 5 5 5 1	0 23.3% 8 19.9% 0 17.8% 4 19.8%	IV, Random, 95% CI -23.56 [-36.69, -10.43] -28.00 [-46.97, -9.03] -26.67 [-49.28, -4.06] -24.30 [-43.37, -5.23] -67.97 [-88.05, -47.89]	Favors LBBP Favors BVP
Test for overall effect B. Procedure Time <u>Study or Subgroup</u> Hua2022 Rademakers2022 Wang2022 Wu 2020 Zu2021	E Z = 3.66 Mean 104.24 109 129.25 98.4 90.08	BBP 5D 17.36 31.69 36.5 33.4	Total 21 31 20 32 13 117	127.3 13 155.9 122.3 158.0	n SI 3 24.7 7 4 2 40.7 7 53.3 5 19.0	1 2 8 3 7 2 5 5 5 1 15	0 23.3% 8 19.9% 0 17.8% 4 19.8% 9 19.2% 1 100.0%	IV, Random, 95% CI -23.56 [-36.69, -10.43] -28.00 [-46.97, -9.03] -26.67 [-49.28, -4.06] -24.30 [-43.37, -5.23] -67.97 [-88.05, -47.89]	Favors LBBP Favors BVP

Figure 5: (A) Fluoroscopy time, minute. (B) Procedure time, minute. SD, standard deviation; CI, confidence interval; LBBP, left bundle branch area pacing; BVP, biventricular pacing.



A. LVEF Improveme		LBBP			BVP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Chen2021	18.52	13.19	49	12.89	9.73	51	4.7%	5.63 [1.07, 10.19]	
Guo2020	20.5	9.6	21	15.4	11.2	21	2.5%	5.10 [-1.21, 11.41]	+
Hua2022	15.66	14.59	21	12.77	11.13	20	1.6%	2.89 [-5.03, 10.81]	
Li2020	17.1	7.2	27	7	7.5	54	8.6%	10.10 [6.73, 13.47]	
Liu2021	17.2	9.3	27	13.7	11.5	35	3.7%	3.50 [-1.68, 8.68]	+
Rademakers2022	15.1	11.7	29	9.3	12.3	36	2.9%	5.80 [-0.05, 11.65]	· · · · · · · · · · · · · · · · · · ·
Wang2020	18.06	9.99	10	12.97	13.37	30	1.6%	5.09 [-2.73, 12.91]	
Wang2022	21.08	1.91	20	15.62	1.94	20	69.1%	5.46 [4.27, 6.65]	- ∎ -
Wu 2020	24	10.9	30	16.7	14.6	49	3.1%	7.30 [1.65, 12.95]	
Zu2021	18.3	10.66	13	13.42	6.87	19	2.3%	4.88 [-1.69, 11.45]	
Total (95% CI)			247			335	100.0%	5.80 [4.80, 6.79]	•
Heterogeneity: Tau ² =	0.00; C	hi ² = 8.2	6. df=	9 (P = 0	.51); I²∍	= 0%			<u> </u>
Test for overall effect									-10 -5 Ó Ś 10 Favors BVP Favors LBBP

B. LVEDD Reduction		LBBP			BVP			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl		
Chen2021	12.57	12.8	49	7.39	18.49	51	9.0%	5.18 [-1.03, 11.39]			
Guo2020	11	16.4	21	9.4	14.4	21	4.3%	1.60 [-7.73, 10.93]			
Hua2022	10.61	11.97	21	5.28	10.81	20	7.3%	5.33 [-1.65, 12.31]	+		
Rademakers2022	6.9	10.3	29	1.6	11.8	36	11.5%	5.30 [-0.08, 10.68]			
Wang2020	11.1	14.83	10	8.74	17.47	30	3.1%	2.36 [-8.76, 13.48]			
Wang2022	11.42	1.22	20	10.64	1.24	20	64.9%	0.78 [0.02, 1.54]	•		
Total (95% CI)			150			178	100.0%	2.11 [0.12, 4.10]	•		
Heterogeneity: Tau ² =	1.43; C	hi² = 6.0)7, df=	5 (P = 0	.30); P ≈	= 18%		-			
Test for overall effect:									-10 -5 Ó 5 10 Favours BVP Favours LBBP		


C. NYHA Class Improv	Ellient L	BBP			BVP			Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl		
Guo2020	1.7	1.6	21	1.5	1.4	21	8.8%	0.20 [-0.71, 1.11]			
Hua2022	1.28	1.46	21	1.11	1.76	20	7.7%	0.17 [-0.82, 1.16]			
Liu2021	1.6	0.6	27	0.9	0.8	35	24.2%	0.70 [0.35, 1.05]	_		
Wang2020	1.4	1.29	10	1.1	1.35	30	8.4%	0.30 [-0.63, 1.23]			
Wang2022	1.22	0.11	20	1.1	0.11	20	34.2%	0.12 [0.05, 0.19]	-		
Wu 2020	1.5	1	30	0.9	1.5	49	16.7%	0.60 [0.05, 1.15]			
Total (95% CI)			129			175	100.0%	0.37 [0.05, 0.68]			
Heterogeneity: Tau ² =				f= 5 (P	= 0.02)	; I² = 61	1%	_	-1 -0.5 0 0.5 1		
Test for overall effect	Z = 2.30	(P=0).02)						Favours BVP Favours LBBP		

prelim
DIC
eI
ę.,
na,
ar
at
ed.
reviewe
evi
peer
een
ot b
nol
has
Ē.
nd
÷.
reprint
ep.
đ
8
This
7
4
016
180
36
1223.
6422
110
.16
au
11
225/
0.2
org/
loi.
ž
ttps://
htt
ermission.
SSI
per
H.
2
10
vitho
3
use w
reuse w
use w
No reuse w
ved. No reuse w
erved. No reuse w
ved. No reuse w
its reserved. No reuse w
ghts reserved. No reuse w
l rights reserved. No reuse w
ghts reserved. No reuse w
. All rights reserved. No reuse w
nder. All rights reserved. No reuse w
nder. All rights reserved. No reuse w
ar/funder. All rights reserved. No reuse w
nder. All rights reserved. No reuse w
e author/funder. All rights reserved. No reuse w
ar/funder. All rights reserved. No reuse w
is the author/funder. All rights reserved. No reuse w
ie author/funder. All rights reserved. No reuse w
is the author/funder. All rights reserved. No reuse w
is the author/funder. All rights reserved. No reuse w
ight holder is the author/funder. All rights reserved. No reuse w
is the author/funder. All rights reserved. No reuse w
copyright holder is the author/funder. All rights reserved. No reuse w
he copyright holder is the author/funder. All rights reserved. No reuse w
copyright holder is the author/funder. All rights reserved. No reuse w
he copyright holder is the author/funder. All rights reserved. No reuse w
3 The copyright holder is the author/funder. All rights reserved. No reuse w
3 The copyright holder is the author/funder. All rights reserved. No reuse w
· 2023 The copyright holder is the author/funder. All rights reserved. No reuse w
1 Mar 2023 The copyright holder is the author/funder. All rights reserved. No reuse w
· 2023 The copyright holder is the author/funder. All rights reserved. No reuse w
1 Mar 2023 The copyright holder is the author/funder. All rights reserved. No reuse w

	and Morta	lity							
Churche on Carbon own	LBB		BVP	Tetal	Mainlet	Risk Ratio		Risk Ratio	
Study or Subgroup Chen2021	Events 2	Total 49	Events 5	Total 51	Weight 15.7%	M-H, Random, 95% Cl 0.42 [0.08, 2.05]		M-H, Random, 95% Cl	
Guo2020	2	49	0	21	15.7%	Not estimable		-	
Hua2022	5	21	12	20	55.7%	0.40 [0.17, 0.92]			
Li2020	Ō	27	0	54		Not estimable			
Rademakers2022	3	29	4	36	19.9%	0.93 [0.23, 3.83]			
Wang2020	0	10	1	30	4.1%	0.94 [0.04, 21.40]			
Wu 2020	0	30	3	49	4.6%	0.23 [0.01, 4.31]			
Total (95% CI)		187		261	100.0%	0.48 [0.25, 0.90]			
Total events	10	107	25	201	100.070	0.40 [0.25, 0.30]			
Heterogeneity: Tau ² =		$i^2 = 1.43$		P = 0.8	(3): $ ^2 = 0.9$	6	<u> </u>		
Test for overall effect:							0.01	0.1 1 10 Favors LBBP Favors BVP	100
B. HEH									
5	LBB		BVP Events		Moight	Risk Ratio M-H, Random, 95% Cl		Risk Ratio	
Study or Subgroup Chen2021	Events 2	10tai 49	Events 5	Total 51	21.2%			M-H, Random, 95% Cl	
Guo2020	2	49	5	21	21.2%	0.42 [0.08, 2.05] Not estimable		-	
Hua2022	4	21	11	20	57.4%	0.35 [0.13, 0.91]			
1 12020	0	27	0	54	57.470	Not estimable		-	
Rademakers2022	1	29	2	36	9.7%	0.62 [0.06, 6.51]			
Wang2020	0	10	1	30	5.5%	0.94 [0.04, 21.40]			
Wu 2020	0	30	3	49	6.3%	0.23 [0.01, 4.31]			
Total (95% CI)		187		261	100.0%	0.39 [0.19, 0.82]			
Total events	7		22				_		
Heterogeneity: Tau ² =				P = 0.9	6); I ² = 09	6	0.01	0.1 1 10	100
Test for overall effect:	Z = 2.50	(P = 0.0)	1)					Favors LBBP Favors BVP	
C. All-cause Mortality	LBB	P	BVP			Risk Ratio		Risk Ratio	
Study or Subgroup					Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Chen2021	0	49	0	51	roigin	Not estimable			
Guo2020	0	21	0	21		Not estimable			
Hua2022	1	21	1	20	33.0%	0.95 [0.06, 14.22]			
Li2020	0	27	, 0	54	33.0 %	Not estimable		T	
Rademakers2022	2	29	2	36	67.0%	1.24 [0.19, 8.28]			
Wang2020	0	10	0	30	07.070	Not estimable			
Wu 2020	0	30	0	49		Not estimable			
			0	40		Notestimable			
Total (95% CI)	0	187		261	100.0%	1.14 [0.24, 5.38]			
Total (95% CI) Total events		187	3	261	100.0%	1.14 [0.24, 5.38]			
Total events	3		3 / df=1 (
Total events Heterogeneity: Tau ² =	3 = 0.00; Ch	i² = 0.0:	2, df = 1 (0.01	0.1 1 10	100
Total events	3 = 0.00; Ch	i² = 0.0:	2, df = 1 (L	0.1 1 10 Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² =	3 = 0.00; Ch	i² = 0.0:	2, df = 1 (0.01		100
Total events Heterogeneity: Tau ² =	3 = 0.00; Ch	i² = 0.0:	2, df = 1 (L 0.01		100
Total events Heterogeneity: Tau ² =	3 = 0.00; Ch	i² = 0.0:	2, df = 1 (0.01		100
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance	3 = 0.00; Ch : Z = 0.16 LBB	ii² = 0.0: (P = 0.8	2, df = 1 (P = 0.8 BVP	8); ² = 09	6 Mean Differen	ice	Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup	3 = 0.00; Ch : Z = 0.16 LBB Mean	ii ² = 0.03 (P = 0.8 P SD Tot	2,df=1(7) al Mean	P = 0.8 BVP	8); ² = 09 5D Total	% Mean Differen Weight IV, Random,	ice 95% Cl	Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup Chen2021 4	3 = 0.00; Ch : Z = 0.16 LBB <u>Mean</u> 30.62 119	i ² = 0.00 (P = 0.8 P <u>SD Tot</u> 3.94	2, df = 1 (7) <u>al Meau</u> 19 434.9-	P = 0.8 BVP 1 S 1 142.9	8); ² = 09 5 <u>D Total</u> 35 51	6 Mean Differen IV, Random, 23.8% -4.32 (-55.06)	ice 95% Cl	Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5	3 = 0.00; Ch : Z = 0.16 LBB <u>Mean</u> 30.62 111 75.81 9	i ² = 0.03 (P = 0.8 <u>SD Tot</u> 3.94 (5.75 (2, df = 1 (7) <u>al Mear</u> 19 434.9- 21 632.8	P = 0.8 BVP 1 5 4 142.9 3 140.8	8); I ² = 09 5 <u>D Total</u> 35 51 37 20	Mean Different Weight IV, Random, 23.8% -4.32 [-55.96, 19.6% -57.07 [-131.16]	ce 95% Cl , 47.32] , 17.02]	Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020	3 = 0.00; Ch : Z = 0.16 <u>LBB Mean</u> 30.62 119 75.81 9: 563.9 12	i [#] = 0.03 (P = 0.8 <u>P</u> <u>SD Tot</u> 3.94 5.75	al <u>Mean</u> 9 434.9- 21 632.8- 27 712	P = 0.8 BVP 1 5 4 142.9 3 140.8 4 189	8); I ² = 09 <u>50 Total</u> 35 51 37 20 .2 54	Mean Different Veight IV, Random, 23.8% -4.32 [-55.96, 19.6% -57.07 [-131.16, 20.7% -14.85 [-216.87,	ce 95% Cl , 47.32] , 17.02] -80.13]	Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5	3 = 0.00; Ch : Z = 0.16 LBB <u>Mean</u> 30.62 111 75.81 9	i ² = 0.00 (P = 0.8 <u>SD Tot</u> 5.75 22.3 67	2, df = 1 (7) <u>al Mear</u> 19 434.9- 21 632.8	P = 0.8 BVP 1 142.9 3 140.8 4 189 3 19	8); ² = 09 50 Total 35 51 37 20 12 54 33 36	Mean Different Weight IV, Random, 23.8% -4.32 [-55.96, 19.6% -57.07 [-131.16]	95% Cl 47.32] 17.02] -80.13] -31.40]	Favors LBBP Favors BVP	100
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup (hen2021 4 Hua2022 5 Li2020 Rademakers2022 Wang2022	3 = 0.00; Ch : Z = 0.16 <u>LBB</u> <u>Mean</u> 30.62 111 75.81 9 563.9 12 509	i ² = 0.00 (P = 0.8 5.05 Tot 3.94 6 5.75 2 22.3 5 67 5 93 5	al Mean 19 434.9: 21 632.8: 27 712. 29 60: 20 59:	P = 0.8 BVP 1 142.9 3 140.8 4 189 3 19	 B); ² = 09 Total 5 51 7 20 .2 54 .3 36 .4 20 	Mean Different Veight V. Random, 23.8% -57.07 [131.16, 20.7% -148.50 [-218.87, 20.8% -99.00 [166.60, 15.0% -116.00 [-218.26,	ce 95% CI , 47.32] , 17.02] -80.13] -31.40] -13.74]	Favors LBBP Favors BVP	100
Total events Heterogeneily: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Kademakers2022 Wang2022 Total (95% CI)	3 = 0.00; Ch : Z = 0.16 <u>LBB</u> <u>Mean</u> 30.62 111 75.81 9 553.9 12 509 476	i ² = 0.0) (P = 0.8 <u>SD Tot</u> 3.94 5.75 5.75 67 93	al Mean al Mean 9 434.9- 11 632.8- 27 712. 29 60: 20 59: 16	P = 0.8 BVP 1 4 142.9 3 140.8 4 189 3 19 2 21	8); ² = 09 50 Total 35 51 37 20 12 54 33 36 14 20 181	Mean Different Weight V, Random, 23.8% -4.32 +55.60, 19.6% -57.07 [-131.16, 20.7% -148.50 [-216.87, 20.8% -99.00 [-166.60,	ce 95% CI , 47.32] , 17.02] -80.13] -31.40] -13.74]	Mean Difference IV, Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup Chen2021 4 Hu2020 Study or Subgroup Rademakers 2022 Wang 2022 Total (95% CI) Heterogeneity: Tau ² = 27	3 = 0.00; Ch : Z = 0.16 Mean 30.62 119 75.81 99 553.9 12 509 476 ***********************************	i ² = 0.00 (P = 0.8 <u>SD Tot</u> 5.75 22.3 67 93 14 ² = 12.88	al Mean al Mean 9 434.9- 11 632.8- 27 712. 29 60: 20 59: 16	P = 0.8 BVP 1 4 142.9 3 140.8 4 189 3 19 2 21	8); ² = 09 50 Total 35 51 37 20 12 54 33 36 14 20 181	Mean Different Veight V. Random, 23.8% -57.07 [131.16, 20.7% -148.50 [-218.87, 20.8% -99.00 [166.60, 15.0% -116.00 [-218.26,	ce 95% CI , 47.32] , 17.02] -80.13] -31.40] -13.74]	Mean Difference N, Random, 95% Cl	100
Total events Heterogeneily: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Kademakers2022 Wang2022 Total (95% CI)	3 = 0.00; Ch : Z = 0.16 Mean 30.62 119 75.81 99 553.9 12 509 476 ***********************************	i ² = 0.00 (P = 0.8 <u>SD Tot</u> 5.75 22.3 67 93 14 ² = 12.88	al Mean al Mean 9 434.9- 11 632.8- 27 712. 29 60: 20 59: 16	P = 0.8 BVP 1 4 142.9 3 140.8 4 189 3 19 2 21	8); ² = 09 50 Total 35 51 37 20 12 54 33 36 14 20 181	Mean Different Veight V. Random, 23.8% -57.07 [131.16, 20.7% -148.50 [-218.87, 20.8% -99.00 [166.60, 15.0% -116.00 [-218.26,	ce 95% CI , 47.32] , 17.02] -80.13] -31.40] -13.74]	Mean Difference IV, Random, 95% Cl	
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Wang2022 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect Z =	3 = 0.00; Ch : Z = 0.16 Mean 30.62 119 75.81 99 553.9 12 509 476 ***********************************	i ² = 0.00 (P = 0.8 <u>SD Tot</u> 5.75 22.3 67 93 14 ² = 12.88	al Mean al Mean 9 434.9- 11 632.8- 27 712. 29 60: 20 59: 16	P = 0.8 BVP 1 4 142.9 3 140.8 4 189 3 19 2 21	8); ² = 09 50 Total 35 51 37 20 12 54 33 36 14 20 181	Mean Different Veight V. Random, 23.8% -57.07 [131.16, 20.7% -148.50 [-218.87, 20.8% -99.00 [166.60, 15.0% -116.00 [-218.26,	ce 95% CI , 47.32] , 17.02] -80.13] -31.40] -13.74]	Mean Difference N, Random, 95% Cl	
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Wang2022 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect Z = B. Pacing threshold	3 = 0.00; Ch : Z = 0.16 : Z = 0.16 : Z = 0.16 : Z = 0.16 : S09 476 : S09 476 : S09 476 : S09 476 : S09 476 : S09 476 : S09 476 : LBB	i ² = 0.03 (P = 0.8 <u>SD Tot</u> 3.94 5.75 5.75 67 5.75 93 57 4 2 = 12.88 0.005) 3P	al Mean 9 434.9 19 434.9 11 632.8 17 712. 19 60 20 59 16 df = 4 (P	P = 0.8 BVP 1 S 4 142.9 3 140.0 3 11 2 21 = 0.01); BVP	8); ² = 09 50 Total 137 20 1.2 54 133 36 14 20 181 ² = 69%	Mean Different Weight N, Random, 23.8% -4.32 + 55 6.8 19.6% -57.07 [+131.16, 20.3% -14.35 0 F 216.87, 20.8% -90.00 [+16.6.0, 15.0% -116.00 [-218.26, 100.0% -81.02 [-137.40, -	ece 95% Cl , 47.32] , 17.02] -80.13] -31.40] -13.74] -24.65]	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Wang2022 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect Z =	3 = 0.00; Ch Z = 0.16 Mean 30.62 111 75.81 99 563.9 12 563.9 12 563.9 12 563.9 12 563.9 12 563.9 12 563.9 12 563.9 12 563.9 12 563.9 12 80.0 12 81.87; Chi = 2.82 (P = LBE Mean	i ² = 0.02 (P = 0.8 (P = 0.8 (P = 0.8 (P = 0.8 (P = 0.8 (P = 0.8 (P = 0.8) (P = 0.8) (P = 0.8) (P = 0.0 (P = 0.8) (P = 0.0) (P = 0.8) (P = 0.8) (al Mean 9 434.9 19 434.9 11 632.8 17 712. 19 60 20 59 16 df = 4 (P	P = 0.8 BVP 1 S 4 142.9 3 140.0 3 11 2 21 = 0.01); BVP	8); ² = 09 50 Total 137 20 1.2 54 133 36 14 20 181 ² = 69%	Mean Different VI. Random, 23.8% -4.32 [+55.0] 19.6% -57.07 [+131.16, 20.7% -14.50 [+218.27, 20.8% -99.00 [+166.60, 15.0% -116.00 [+218.26, 100.0% -81.02 [-137.40, -	ece 95% Cl , 47.32] , 17.02] -80.13] -31.40] -13.74] -24.65]	Mean Difference IV. Random, 95% CI	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup Chen2021 4 Hua2022 5 IZ020 Rademakers2022 Wang2022 Total (95% C)) Heterogeneity: Tau ² = 27 Test for overall effect: Z = B. Pacing threshold Study or Subgroup Chen2021	3 = 0.00; Ch : Z = 0.16 Mean 30.62 111 75.81 92 509 476 *81.87; Chi = 2.82 (P = LBE Mean 1 0.92	i ² = 0.02 (P = 0.8 (P = 0.8) (P = 0.8 (P = 0.8) (P	al Mean 99 434.9 11 632.8 27 712. 9 60 0 59 16 6 , df = 4 (P al Mean 9 1.45	P = 0.8 BVP 1 S 4 142.9 3 140.0 4 189 3 14 2 21 = 0.01); BVP SD 0.39	8); ² = 09 50 Total 35 51 37 20 12 54 13 36 14 20 181 ² = 69% Total V 51 2	Mean Different IV, Random, 23.8% Mean Different IV, Random, 4.32 (+55.0) 19.6% -57.07 [+131.16, 20.7% -14.50 [+131.16, 20.7% 20.7% -14.50 [+21.82, 15.0% -116.00 [+218.26, 100.0% 100.0% -81.02 [-137.40, - 0.53 [+0.65, -0.4]	ce 95% CI , 47.32) , 17.02 -80.13] -31.40] -13.74] -24.65] - CI CI	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Wang2022 Total (95% Ct) Heterogeneity: Tau ² = 27 Test for overall effect 2 = B. Pacing threshold Study or Subgroup Chen2021 Guu2020	3 = 0.00; Ch : Z = 0.16 Mean 30.62 111 75.81 92 5039 12 509 476 781.87; Chi = 2.82 (P = LBE Mean 0.92 10 0.48 0 0.48	P SD Tot 0.94 ↔ 22.3 ÷ = 12.88 0.0005) 3P SD Tot 0.2 ↔ 0.2 ↔	al Mean 9 434.9 1 632.8 7 712. 9 600 20 59 16 , df = 4 (P al Mean 9 1.45 1 1.12	P = 0.8 BVP 1 S 4 142.0 3 140.0 4 189 3 140.0 14 189 5 2 21 = 0.01); BVP SD 0.39 0.46	8); ² = 09 50 Total 15 51 17 20 12 54 13 36 14 20 181 ² = 69% Total W 51 2 21 1 21 1	Mean Different Weight N, Random, 23.8% -57.07 [+31.16, 20.7% -14.35 [-52.16.87, 20.8% -99.00 [+66.60, 15.0% -116.00 [-218.26, 100.0% -81.02 [-137.40, -81.02 [-137.40, -81.02 [-137.40, -95%] Mean Difference Mean Difference -61.03 [-0.65, -0.4] -0.53 [-0.65, -0.4] -0.54 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -0.55 [-0.86, -0.4] -	ece 95% CI , 47.32] , 47.02] -80.13] -31.40] -13.74] -24.65] - CI 41] 42]	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup Chen2021 4 Hua2022 5 Rademakers 2022 Wang 2022 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect: Z = B. Pacing threshold Study or Subgroup Chen2021 Quo 2020 Hua2022	3 = 0.00; Ch : Z = 0.16 Mean 30.62 111 75.81 9 563.9 12 509 476 81.87; Chi = 2.82 (P = LBE Mean 0.92 1 0.92 1 0.92 1	P SD Tot 93 5.75 67 7 14 ***=12.88 SD Tot 0.02 4 SD Tot 0.22 2.22 0.12 2.22 0.12 2.22 0.12 2.22 0.12 0.12 1.22	al Mean 9 434.9- 19 434.9- 11 632.8- 12 600 10 59: 16 14 (P al Mean 9 1.45 11 1.12	P = 0.8 BVP 1 S 4 142.9 3 140.0 3 140.0 5 1 1 2 21 1 1 1 1 1 1 1 1	8); ² = 09 50 Total 37 20 12 54 33 36 14 20 181 ² = 69% Total V 51 2 21 1 20 1	Mean Different Weight N, Random, 23.8% -4.32 [-55.96, 19.6% -57.07 [-131.16, 20.7% -14.50 [-218.27, 20.8% -99.00 [-166.60, 15.0% -116.00 [-218.26, 100.0% -81.02 [-137.40, Mean Difference /eight N, Random, 95% 20.4% -0.53 [-0.65, -0.4 10.9% -0.64 [-0.86, -0.4 31.5% -0.46 [-0.65, -0.4	ce 95% CI 47.32] (17.02) -80.13] -31.40] -13.74] -24.65] - - - - - - - - - - - - - - - - - - -	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup Chen2021 4 Hua2022 7 U2020 Rademakers2022 Wang2022 Total e95% (C) Heterogeneity: Tau ² = 27 Test for overall effect: Z = B. Pacing threshold Study or Subgroup Chen2021 Quo2020 Hua2022 Li2020	3 = 0.00; Ch : Z = 0.16 Kean 509 476 *81.87; Chi = 2.82 (P = Kean 0.92 0.92 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75	P SD Tot 3.94 	al Mean 9 434.9 19 434.9 11 632.8 17 712. 19 60 20 59: 16 10 1.45 11 1.12 11 1.16 17 1.43	P = 0.8 BVP 1 S 4 142.2 3 140.3 4 142.2 2 21 = 0.01); BVP SD 0.39 0.46 0.42 0.74	8); ² = 09 <u>D Total</u> <u>15</u> 51 <u>37</u> 20 <u>12</u> 54 <u>33</u> 36 <u>14</u> 20 <u>181</u> ² = 69% <u>Total V</u> <u>51</u> 2 <u>21</u> 1 <u>20</u> 1 <u>54</u> 3 <u>54</u> 3 <u>51</u> 2 <u>51</u> 3 <u>51</u> 2 <u>51</u> 3 <u>51</u> 2 <u>51</u> 3 <u>51</u>	Mean Difference Viewight IV. Random, IV. Random, 23.8% -4.32 [+55.06] 19.6% -57.07 [+131.16, 20.7% -148.05 [+218.87, 100.0% -9.00 [+166.60, 15.0% 100.0% -81.02 [-137.40, - Mean Difference Velam Difference Velam Difference Volam Difference 0.9% -0.53 [-0.65, -0.4 0.9% -0.64 [-0.86, -0.4 0.2% -0.68 [-0.91, -0.4	cce 95% CI , 47.32] , 17.02 -80.13] -31.40] -13.74] -24.65] - - - - - - - - - - - - - - - - - - -	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Wang2022 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect 2 = B. Pacing threshold Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022	3 = 0.00; Ch : Z = 0.16 Mean 30.62 116 75.81 92 563.9 12 509 476 781.87; Chi = 2.82 (P = LBE Mean 0.92 1 0.48 0 0.48 0 0.48 0 0.75 0 0.75 0 0.75 0	P SD Tot 93 14 = 12.88 0.005) 3P 5D Tot 0.2 4 0.22 2 0.1 2 0.1 3 0.2 4 0.2 2 0.1 3 0.2 4 0.2 2 0.1 3 0.1 4 0.2 2 0.1 1 0.1 4 0.1 4 0.	al Mean 9 434.9: 1 632.8: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.13: 1 1.13: 1 1.14: 1 1.14:	P = 0.8 P = 0.9 P =	8); ² = 09 30 <u>Total</u> 37 20 12 54 33 36 14 20 Total V Total V 51 2 20 1 54 3 54 4 20 1 54 1 20 1 54 1 20 1 54 3 51 3	Mean Different Weight N, Random, 238% -432 F5568, 19.6% -57.07 [+31.16, 20.7% -1432 F558, 20.8% -92.00 [+66.60, 15.0% -116.00 [-218.26, 100.0% -81.02 [-137.40, -81.02 [-137.40, -0.63 [-0.65, -0.4] -0.53 [-0.65, -0.4] -0.53 [-0.65, -0.4] -0.46 [-0.65, -0.2] -0.64 [-0.86, -0.4] -0.64 [-0.86, -0.4] -0.68 [-0.91, -0.4] -0.68 [-0.91, -0.4] -0.53 [-0.7] -0.68 [-0.91, -0.4] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.55 [-0.2] -0.53 [-0.7] -0.53 [-	ce 95% CI 47.32] -71.02] -80.13] -31.40] -13.74] -24.65] -24.65] -24.65] -24.65] -24.65] -24.65] -24.65] -24.65] -24.65] -24.65] -25]	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup Chen2021 4 Hu2020 Chen2021 4 Hu2020 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect: Z = B. Pacing threshold Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022 Wang2020	3 = 0.00; Ch : Z = 0.16 Mean 30.62 111 75.81 9 563.9 12 509 476 81.87; Chi = 2.82 (P LBB Mean 0.92 1 0.92 1 0.92 1 0.92 1 0.92 1 0.75 0 0.7 1 0.59 0	P SD Tor 9.94 	al Mean 9 434.9: 11 632.8: 17 712. 9 60: 10 53. 16 6 11 1.2: 11 1.16 17 1.43 1.5 0 1.09 1.5	P = 0.8 P = 0.01 P = 0.01 P = 0.03 P = 0.42 P = 0.42 P = 0.01 P = 0.01 P = 0.42 P = 0.42 P = 0.8 P = 0.01 P = 0.01	B); I ² = 09 30 35 37 20 2 33 36 14 20 181 I ² = 69% 51 21 201 120 1 54 30	Mean Different IV, Random, 23.8% -4.32 [-55.96, 19.8% -57.07 [-131.16, 20.7% -14.85.0 [-218.27, 20.8% -99.00 [-166.60, 15.0% -116.00 [-218.26, 100.0% -81.02 [-137.40,- Mean Difference /eight /V, Random, 95% 20.4% -0.53 [-0.65, -0.4 0.9% -0.68 [-0.91, -0.4 1.1% -0.46 (-0.65, -0.2 0.2% -0.68 [-0.91, -0.4 1.5% -0.80 [-1.01, -0.5 3.6% -0.50 [-0.68, -0.03	cce <u>95% CI</u> , 47.32] , 17.02] -80.13] -81.40] -13.74] -24.65] - <u>CI</u> 41] 42] 27] 45] 59] - 32]	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	
Total events Heterogeneity: Tau ² = Test for overall effect: A. Impedance Study or Subgroup 1 Chen2021 4 Hua2022 5 Li2020 Wang2022 Total (95% CI) Heterogeneity: Tau ² = 27 Test for overall effect 2 = B. Pacing threshold Study or Subgroup Chen2021 Guo2020 Hua2022 Li2020 Rademakers2022	3 = 0.00; Ch : Z = 0.16 Kean 30.62 115 50.9 476 *81.87; Chi = 2.82 (P Kean 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.7 0.02 0.7 0.02 0.7 0.02 0.7 0.02 0.7 0.02 0.7 0.02 0.7 0.02 0.	P SD Tot 94 575 93 94 94 94 95	al Mean 9 434.9: 1 632.8: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.12: 1 1.13: 1 1.13: 1 1.14: 1 1.14:	P = 0.8 BVP 1 42.2 3 140.0 4 189 3 11 2 21 = 0.01); BVP SD 0.39 0.46 0.46 0.45 0.67	8); ² = 09 50 Total 16 51 17 20 13 36 14 20 181 ² = 69% Total W 51 2 21 1 20 1 36 1 36 1 30 1 30 1 30 1 30 1	Mean Different Weight N, Random, 238% -432 F5568, 19.6% -57.07 [+31.16, 20.7% -1432 F558, 20.8% -92.00 [+66.60, 15.0% -116.00 [-218.26, 100.0% -81.02 [-137.40, -81.02 [-137.40, -0.63 [-0.65, -0.4] -0.53 [-0.65, -0.4] -0.53 [-0.65, -0.4] -0.46 [-0.65, -0.2] -0.64 [-0.86, -0.4] -0.64 [-0.86, -0.4] -0.68 [-0.91, -0.4] -0.68 [-0.91, -0.4] -0.53 [-0.7] -0.68 [-0.91, -0.4] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.53 [-0.7] -0.55 [-0.2] -0.53 [-0.7] -0.53 [-	ce <u>95% CI</u> , 47.32] , 47.32] -80.13] -31.40] -31.40] -31.40] -31.40] -31.40] -31.40] -31.40] -24.65] -27] -27] -27] -27] -27] -27] -27] -21] -29] -21] -27] -27] -27] -27] -21] -2	Favors LBBP Favors BVP Mean Difference IV, Random, 95% CI -200 -100 0 100 Favours LBBP Favours EVP Mean Difference	

-1 -0.5 0 0.5 1 Favors LBBP Favors BVP

C. QRSd Reduction		LBBP			BVP			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Chen2021	77.51	15.48	49	49.15	11.96	51	18.4%	28.36 [22.92, 33.80]	
Guo2020	56.2	14.7	21	32.3	14.6	21	13.6%	23.90 [15.04, 32.76]	
Hua2022	48.62	26.29	21	20.65	28.28	20	6.6%	27.97 [11.24, 44.70]	
Liu2021	64.1	18.9	27	32.5	22.3	35	11.9%	31.60 [21.33, 41.87]	
Rademakers2022	43.8	17.1	29	14.9	25.7	36	11.7%	28.90 [18.45, 39.35]	
Wang2020	60.8	20.09	10	33	21.48	30	7.9%	27.80 [13.17, 42.43]	
Wang2022	43.1	18.99	20	38.1	19.11	20	10.3%	5.00 [-6.81, 16.81]	
Wu 2020	56	21.75	30	26	21.75	49	12.4%	30.00 [20.12, 39.88]	
Zu2021	50.3	23.79	13	33.15	20.22	19	7.1%	17.15 [1.34, 32.96]	
Total (95% CI)			220			281	100.0%	25.13 [20.06, 30.20]	•
Heterogeneity: Tau ² =	28.62; (Chi ² = 1	6.47. di	f = 8 (P =	= 0.04);	l² = 51	%		ten de de ce
Test for overall effect:									-50 -25 0 25 50 Favors BVP Favors LBBP



Hosted file

Figure Captions.docx available at https://authorea.com/users/590877/articles/627027-left-bundle-branch-area-pacing-for-heart-failure-patients-requiring-cardiac-resynchronization-therapy-a-meta-analysis

Hosted file

Tables.docx available at https://authorea.com/users/590877/articles/627027-left-bundlebranch-area-pacing-for-heart-failure-patients-requiring-cardiac-resynchronizationtherapy-a-meta-analysis